IN2014CN02399A - - Google Patents
Info
- Publication number
- IN2014CN02399A IN2014CN02399A IN2399CHN2014A IN2014CN02399A IN 2014CN02399 A IN2014CN02399 A IN 2014CN02399A IN 2399CHN2014 A IN2399CHN2014 A IN 2399CHN2014A IN 2014CN02399 A IN2014CN02399 A IN 2014CN02399A
- Authority
- IN
- India
- Prior art keywords
- amino acid
- glycosylated
- somatostatin
- glycosylated polypeptide
- somatostatins
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- 108050001286 Somatostatin Receptor Proteins 0.000 abstract 1
- 102000011096 Somatostatin receptor Human genes 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011192202 | 2011-09-04 | ||
| PCT/JP2012/072380 WO2013032011A1 (ja) | 2011-09-04 | 2012-09-03 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02399A true IN2014CN02399A (en:Method) | 2015-06-19 |
Family
ID=47756483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2399CHN2014 IN2014CN02399A (en:Method) | 2011-09-04 | 2012-09-03 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9422357B2 (en:Method) |
| EP (1) | EP2752424B1 (en:Method) |
| JP (1) | JP6178238B2 (en:Method) |
| KR (1) | KR102031998B1 (en:Method) |
| CN (2) | CN103930441B (en:Method) |
| AU (1) | AU2012302636B2 (en:Method) |
| BR (1) | BR112014004784A2 (en:Method) |
| CA (1) | CA2847334C (en:Method) |
| DK (1) | DK2752424T3 (en:Method) |
| IN (1) | IN2014CN02399A (en:Method) |
| RU (1) | RU2624034C2 (en:Method) |
| SG (2) | SG11201400289SA (en:Method) |
| TW (1) | TWI662966B (en:Method) |
| WO (1) | WO2013032011A1 (en:Method) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012302637B2 (en) | 2011-09-04 | 2016-09-15 | Glytech, Inc. | Glycosylated polypeptide and drug composition containing said polypeptide |
| SG11201400289SA (en) * | 2011-09-04 | 2014-05-29 | Glytech Inc | Glycosylated polypeptide and drug composition containing said polypeptide |
| CN111855827B (zh) * | 2019-04-24 | 2022-09-16 | 岛津企业管理（中国）有限公司 | 多糖蛋白结合疫苗中多糖蛋白结合位点结合率的测定方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4000259A (en) * | 1975-06-16 | 1976-12-28 | American Home Products Corporation | Cyclic dodecapeptide analogs of somatostatin and intermediates |
| US4380953A (en) | 1978-09-11 | 1983-04-26 | Filper Corporation | Transfer mechanism in a peach pitter |
| US4310518A (en) | 1979-10-31 | 1982-01-12 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4235886A (en) | 1979-10-31 | 1980-11-25 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4280953A (en) * | 1979-11-08 | 1981-07-28 | The Salk Institute For Biological Studies | Glycosylated analogs of somatostatin |
| US4316891A (en) * | 1980-06-14 | 1982-02-23 | The Salk Institute For Biological Studies | Extended N-terminal somatostatin |
| LU85269A1 (fr) * | 1984-03-26 | 1985-10-14 | Techland S A | Composes nouveaux de somatostatine,procede pour leur synthese,preparation a usage veterinaire contenant lesdits composes et procede pour le traitement d'animaux |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| HU906340D0 (en) | 1986-10-13 | 1991-04-29 | Sandoz Ag | Synthesis in solid phase for producing peptonic alcohols |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| EP0843725B1 (en) * | 1995-08-11 | 2002-04-17 | Novozymes A/S | Method for preparing polypeptide variants |
| US5750499A (en) | 1995-10-18 | 1998-05-12 | The Salk Institute For Biological Studies | Receptor-selective somatostatin analogs |
| FI965181A7 (fi) | 1996-12-20 | 1998-06-21 | Map Medical Tech Oy | Polyalkoholi-peptidijohdannaiset |
| JP3385947B2 (ja) | 1998-01-05 | 2003-03-10 | 松下電器産業株式会社 | バルクフィーダ |
| EP1198565A1 (en) * | 1999-07-07 | 2002-04-24 | Maxygen Aps | A method for preparing modified polypeptides |
| US20030036181A1 (en) * | 2000-06-30 | 2003-02-20 | Okkels Jens Sigurd | Peptide extended glycosylated polypeptides |
| EP1381396B1 (en) * | 2001-04-23 | 2009-04-01 | Mallinckrodt Inc. | Tc and re labeled radioactive glycosylated octreotide derivatives |
| EP1405858B1 (en) | 2001-06-19 | 2013-01-02 | Glytech, Inc. | Process for producing sugar chain asparagine derivative |
| US7943763B2 (en) | 2002-07-05 | 2011-05-17 | Otsuka Chemical Holdings Co., Ltd. | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides |
| TWI330641B (en) | 2002-12-24 | 2010-09-21 | Yasuhiro Kajihara | Sugar chain asparagine derivatives |
| CN100413889C (zh) * | 2002-12-24 | 2008-08-27 | 大塚化学株式会社 | 糖链天冬酰胺衍生物、糖链天冬酰胺和糖链以及它们的制造方法 |
| WO2004058824A1 (ja) | 2002-12-26 | 2004-07-15 | Otsuka Chemical Co., Ltd. | ３分岐型糖鎖アスパラギン誘導体、該糖鎖アスパラギン、該糖鎖およびそれらの製造方法 |
| HUE041502T2 (hu) | 2003-02-04 | 2019-05-28 | Glytech Inc | Eljárás aszparaginszármazékok elõállítására, amelyeknek vannak cukorláncai |
| WO2004101619A1 (ja) * | 2003-05-15 | 2004-11-25 | Shionogi Co., Ltd. | 機能的糖ペプチドの合理的設計および合成 |
| AU2004259306B2 (en) | 2003-07-28 | 2008-12-18 | Glytech, Inc. | Aminated complex-type sugar chain derivatives and process for the production thereof |
| KR100604994B1 (ko) * | 2004-01-30 | 2006-07-26 | 한국생명공학연구원 | 알파1,6-만노실트랜스퍼라제를 코딩하는 한세눌라폴리모르파 기원의 신규 유전자 및 상기 유전자가 결손된한세눌라 폴리모르파 변이주를 이용한 재조합 당단백질생산 방법 |
| TWI342880B (en) | 2005-07-19 | 2011-06-01 | Otsuka Chemical Co Ltd | Method for producing sugar chain derivatives, and sugar chain derivatives |
| US20070025910A1 (en) * | 2005-07-29 | 2007-02-01 | Norenberg Jeffrey P | Anticancer therapy |
| EP1941902A1 (en) * | 2007-01-02 | 2008-07-09 | Novartis AG | Use of Somatostatin analogs in cluster headache |
| CN102015761A (zh) * | 2007-06-19 | 2011-04-13 | 大塚化学株式会社 | 附加糖链的glp-1肽 |
| JP2011512134A (ja) | 2008-02-19 | 2011-04-21 | アステリオン・リミテッド | 修飾リンカー |
| CN102083854A (zh) * | 2008-06-17 | 2011-06-01 | 大塚化学株式会社 | 附加了糖链的glp-1肽 |
| JP2011525800A (ja) * | 2008-06-27 | 2011-09-29 | ノボ ノルディスク ヘルス ケア アーゲー | 長時間にわたる循環半減期を有するｎ−グリコシル化ヒト成長ホルモン |
| AU2012302637B2 (en) | 2011-09-04 | 2016-09-15 | Glytech, Inc. | Glycosylated polypeptide and drug composition containing said polypeptide |
| SG11201400289SA (en) * | 2011-09-04 | 2014-05-29 | Glytech Inc | Glycosylated polypeptide and drug composition containing said polypeptide |
-
2012
- 2012-09-03 SG SG11201400289SA patent/SG11201400289SA/en unknown
- 2012-09-03 RU RU2014112046A patent/RU2624034C2/ru active
- 2012-09-03 JP JP2013531454A patent/JP6178238B2/ja active Active
- 2012-09-03 SG SG10201601324VA patent/SG10201601324VA/en unknown
- 2012-09-03 EP EP12828271.2A patent/EP2752424B1/en active Active
- 2012-09-03 CN CN201280053754.2A patent/CN103930441B/zh active Active
- 2012-09-03 DK DK12828271T patent/DK2752424T3/da active
- 2012-09-03 WO PCT/JP2012/072380 patent/WO2013032011A1/ja active Application Filing
- 2012-09-03 CA CA2847334A patent/CA2847334C/en active Active
- 2012-09-03 AU AU2012302636A patent/AU2012302636B2/en active Active
- 2012-09-03 US US14/342,359 patent/US9422357B2/en active Active
- 2012-09-03 CN CN201710964257.2A patent/CN107522779B/zh active Active
- 2012-09-03 KR KR1020147008130A patent/KR102031998B1/ko active Active
- 2012-09-03 BR BR112014004784A patent/BR112014004784A2/pt not_active IP Right Cessation
- 2012-09-03 IN IN2399CHN2014 patent/IN2014CN02399A/en unknown
- 2012-09-04 TW TW101132259A patent/TWI662966B/zh active
-
2016
- 2016-07-08 US US15/205,960 patent/US9937264B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140336116A1 (en) | 2014-11-13 |
| CA2847334A1 (en) | 2013-03-07 |
| RU2624034C2 (ru) | 2017-06-30 |
| CA2847334C (en) | 2020-09-01 |
| CN103930441A (zh) | 2014-07-16 |
| CN103930441B (zh) | 2017-11-17 |
| EP2752424A4 (en) | 2015-04-22 |
| JP6178238B2 (ja) | 2017-08-09 |
| BR112014004784A2 (pt) | 2017-03-21 |
| SG10201601324VA (en) | 2016-03-30 |
| CN107522779A (zh) | 2017-12-29 |
| DK2752424T3 (da) | 2019-11-18 |
| US9937264B2 (en) | 2018-04-10 |
| US9422357B2 (en) | 2016-08-23 |
| AU2012302636B2 (en) | 2016-09-15 |
| EP2752424A1 (en) | 2014-07-09 |
| US20170157260A1 (en) | 2017-06-08 |
| RU2014112046A (ru) | 2015-11-27 |
| WO2013032011A1 (ja) | 2013-03-07 |
| TWI662966B (zh) | 2019-06-21 |
| SG11201400289SA (en) | 2014-05-29 |
| CN107522779B (zh) | 2021-10-26 |
| AU2012302636A1 (en) | 2014-03-20 |
| TW201315478A (zh) | 2013-04-16 |
| KR20140059829A (ko) | 2014-05-16 |
| KR102031998B1 (ko) | 2019-10-14 |
| JPWO2013032011A1 (ja) | 2015-03-23 |
| EP2752424B1 (en) | 2019-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500517A1 (en) | Long-acting formulations of insulins | |
| IL255327B (en) | Preparations that include recombinant von willebrand factor (rvwf) protein and a cell culture solution that encodes rvwf | |
| ZA201308251B (en) | Amino acid sequence presenting fusion polypeptide and its use | |
| EP2408921A4 (en) | MODIFICATION OF CXCR4 USING MODIFIED ZINC FINGER PROTEINS | |
| ZA201400490B (en) | Arginine- free tnfr: fc- fusion polypeptide compositions and methods of use | |
| PH12015500636A1 (en) | Nutritional compositions including a calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes | |
| PH12012501842A1 (en) | Low protein infant formula with increased essential amino acids | |
| IL224441B (en) | Antibodies with modified isoelectric points | |
| DK2603596T3 (da) | Sammensætninger, som omfatter et polypeptid med cellulolyseforbedrende aktivitet og en væske, og anvendelser deraf | |
| MX2013006171A (es) | Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico. | |
| DK2390265T3 (da) | Insulinotropisk peptidderivat med modificeret N-terminal aminosyre | |
| IN2012DN00377A (en:Method) | ||
| EA201490070A1 (ru) | Коантагонисты глюкагонового рецептора/glp-1-рецептора | |
| MX2014011459A (es) | Proteinas nutritivas cargadas y metodos. | |
| BRPI0904622A2 (pt) | peptídeo com ação de prolongar a meia-vida de um peptídeo de interesse no plasma | |
| NZ606250A (en) | Methods of inhibition of protein fucosylation in vivo using fucose analogs | |
| WO2013186240A3 (en) | Exendin-4 peptide analogues | |
| BR112014014913A2 (pt) | mutante prongf e método de preparação de uma beta-ngf humana biologicamente ativa | |
| IL220284A0 (en) | Insulin analogues with chlorinated amino acids, compositions comprising the same and uses thereof | |
| WO2012068317A3 (en) | Methods for producing recombinant proteins | |
| IL231421A (en) | Lupane and its similar compounds are preserved in position 3ß by carboxy-alkyl-carbonyl-oxy and position 17- by (alkyl-conserved) amino, and also anti-HIV drug preparations containing them | |
| MX2014011614A (es) | Fragmentos y proteinas nutritivas con fenilalanina baja o nula y metodos. | |
| EA201290542A1 (ru) | Модифицированные свиные соматотропиновые полипептиды и их применение | |
| EA201290541A1 (ru) | Модифицированные бычьи соматотропиновые полипептиды и их применение | |
| GB2517354A (en) | Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy |